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ELECTROCARDIOGRAPHIC CHANGES IN CHILDREN TREATED WITH 
ZIPRASIDONE: A PROSPECTIVE STUDY AND REVIEW 
Jennifer Blair, Lawrence Scahill, Matthew State, and Andres Martin. Yale Child Study 
Center, New Haven, CT. 
This study assessed the electrocardiographic (ECG) safety profile of low-dose 
ziprasidone (Geodon) (< 60 mg/day) among pediatric outpatients treated for up to six 
months, and compared electrocardiographic intervals generated through manual versus 
automatic methods. Literature on the electrocardiographic safety in children of three 
major classes of psychoactive medications, as well as on the vicissitudes of the 
electrocardiographic QTc interval as a marker for clinical risk, is also reviewed, and 
safety guidelines are presented. The study was a prospective, open-label trial involving 
20 subjects with a mean age of 13.2 ± 3.0 years. Subjects received a mean ziprasidone 
dosage of 30 ± 13 mg/day and were followed for 4.6 ± 2.0 months, receiving a median of 
9 ECGs each. There were statistically significant changes from baseline to peak values in 
heart rate, PR and QTc intervals, but not in QRS complex width. The mean QTc interval 
increase from baseline to peak was 28 ± 26 milliseconds (msec), and not related to 
dosage (r = 0.16, p = 0.07). The peak QTc of three subjects reached or exceeded 450 
msec. One subject experienced a 114-msec prolongation. There was poor agreement (k= 
0.25) between automated and manual identification of prolonged QTc intervals (> 440 
msec). In low doses, ziprasidone causes a clinically significant increase in the QTc 
interval in children and adolescents. Periodic ECG monitoring is warranted when 
prescribing ziprasidone to children, particularly at higher doses. Automated 
measurements of the QTc interval should not be relied upon to evaluate prolongation. 
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1 
PREFACE 
Psychiatry, while primarily concerned with mental illness, is also properly 
involved with the care of other organ systems. Many mental illnesses can wreak havoc 
on the body, whether because of inherent physiologic associations with the primary 
disorder, behavioral changes leading to self-abuse or neglect, or medications used to treat 
their manifestations. 
Ties between the mind and the cardiovascular system are increasingly being 
described, as our understanding of the nervous system and its effects on heart rate and 
other parameters grows. Immediate daily concerns for the practicing psychiatrist arise 
because many of the drugs in his armamentarium exert direct and potentially deleterious 
effects on the heart - effects that can be visualized by, among other means, the 
electrocardiogram (ECG). Prolongation of the corrected QT interval is considered the 
most worrisome manifestation of a psychoactive medication’s effect on the ECG, because 
such prolongation may be associated with lethal arrhythmia and sudden death. Children 
are not immune from these effects, which have been noted most conspicuously in this 
population in association with the tricyclic antidepressants. The precise mechanism for 
all ECG changes is not fully understood, but it is known that blockade of sodium 
channels is often the culprit in cases of QTc prolongation. In turn, QTc prolongation is 
associated with torsades de pointes, an arrhythmia which may be fatal. Because of the 
potential lethality of the drugs in question, it is important to be able to monitor the patient 
for warning signs. 
It is then that the accuracy of the ECG becomes a vital issue. The QTc interval, 
while at present our best means of predicting dangerous arrhythmias, is in many ways a 

problematic parameter. It is corrected for heart rate, but is inaccurate at extremely slow 
or fast rates. Many nonpathologic factors affect its duration, such as gender, age, time of 
day, and postprandial state. The way in which the QTc is measured varies, along with 
accuracy. Even the cutoff time for dangerous prolongation is not universally agreed 
upon. In children, the problem is even less clear-cut. Children were seldom included in 
early studies which devised QT correction formulas, so it is not clear how well the most 
popular formulas apply. Experience with pediatric patients and many psychiatric 
medications is typically less extensive than with adults, with a resulting lower power to 
predict and study adverse events. 
This thesis contains three main parts. A literature-based discussion of the 
intricacies of measurement and inteipretation of the QTc parameter is followed by a 
review of the literature regarding the three classes of psychotropic medications with the 
greatest potential to cause QTc prolongation, specifically as they have been studied in 
pediatric patients. These are followed by a report of a prospective, open-label study of 
the effect upon QTc of a new atypical antipsychotic medication in twenty children and 
adolescents, as well as of the comparative reliability of two methods of measuring that 
interval. 
It is hoped that this thesis will shed some light on these complex issues and 
provide some guidance to child psychiatrists who may be unfamiliar with the finer points 
of the cardiac effects of the drugs they rely upon, and of the limitations of the 
measurement methods used to detect those effects. 
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INTRODUCTION AND BACKGROUND 
Some of the more serious complications of pharmacologic therapy in psychiatry 
are cardiac, and range from benign changes in heart rate and blood pressure to heart 
block, potentially lethal arrhythmias, and sudden death. Many of these changes, whether 
silent or symptomatic, can be detected by electrocardiogram (ECG) - prolongation of the 
QTc being a prominent example. There are often few data regarding the safety of 
psychiatric medications in children and adolescents, so the use of these drugs requires 
heightened caution. These concerns have gained clinical immediacy in the wake of: a) 
reports of sudden deaths associated with the tricyclic antidepressant desipramine (1), b) 
concerns over the potential cardiotoxicity of combining stimulants and alpha agonists in 
the treatment of attention deficit-hyperactivity disorder (2), and c) widespread use in 
children and adolescents of antipsychotic drugs - both traditional and atypical - known to 
have direct cardiac effects. After reviewing key points about the QTc interval, this 
section reviews the most important psychiatric medications that cause ECG changes in 
children, with a particular focus on prolongation of the QTc interval, and proposes 
recommendations for screening and monitoring during treatment. 
Search strategy for literature review 
MEDLINE (1966-2003) and EMBASE (1980-2003) searches were conducted for 
each of the drugs discussed below, with the following strategy: the drug’s generic name 
was combined with each of the terms electrocardiogram, overdose, sudden death, 
arrhythmia, and torsades de pointes. These searches were then repeated with the 
additional term child. Relevant articles were identified from search results, and 
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additional articles were identified from bibliographies. Except where otherwise noted, 
the search was last updated in September, 2003. 
The QTc interval: cardiac electrophysiology and clinical measurement 
The QT interval of the ECG is the measured distance between the beginning of 
the QRS complex and the end of the T wave; it comprises depolarization and 
repolarization of the ventricles, and reflects the many processes that go to make up those 
events. Depolarization in myocytes is mediated by influx of sodium and calcium, while 
repolarization is mediated through outflow of potassium; anything that alters the balance 
of ion flux in favor of more positive intracellular ions can lead to prolongation of the QT 
(3). The rapidly-activating potassium rectifier channel, IKr, which is encoded by the 
human ether-a-go-go gene (HERG), is crucial to repolarization; mutations in this gene 
underlie some forms of congenital long QT syndrome (LQTS), while inhibition of the 
channel by medications may explain their QT-prolonging effects (4, 5). Several other 
genes encoding parts of the membrane potassium (IKs) and sodium channel proteins have 
also been identified in LQTS (6-8). 
The QT interval shortens with increasing heart rate, and is usually corrected to 
yield the QTc. This parameter, used in research for several decades, is considered the 
best marker available for predicting lethal arrhythmias. QT dispersion, or the difference 
in QT intervals between leads on the same ECG, is being studied, but has not superseded 
the QTc (9-11). Torsades de pointes (TP), first described in 1966 (12), is an often lethal 
arrhythmia that is almost always preceded by a lengthened QTc interval, and is often 
associated with the sudden deaths of patients on QTc-prolonging medications and those 
with congenital LQTS. It is hypothesized to follow early afterdepolarizations - 
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spontaneous depolarizations occurring in nonpacemaker cells - made possible by delayed 
repolarization (13). Though the exact value is not completely clear, many workers agree 
that a QTc > 500 msec leads to an elevated risk of this arrhythmia, though a direct 
relationship between QTc prolongation and risk of arrhythmia is not necessarily present 
in drug-induced cases (13) (it has been established in congenital LQTS (14)). Some 
drugs cause marked prolongations without serious sequelae - amiodarone, for example, 
though it may lengthen the QTc to greater than 600 msec, is rarely associated with TP 
(15) - while others are associated with TP at a shorter QTc (16). 
The QTc is an imperfect parameter, however. Even for the simple correction for 
heart rate, many formulae have been proposed, but none is universally applicable. The 
most popular, the Bazett formula (17), divides the QT by the square root of the R-R 
interval. Yet this formula derives from a study that examined only 39 adult subjects, and 
is known to be nonlinear at fast heart rates (11). Despite these shortcomings, the formula 
is used widely, which simplifies comparisons between different studies. Other formulas 
are available, including some derived from studies which included children (10), but 
these are not in general use. Some workers argue that the QT/RR relationship exhibits so 
much inter-individual variability that a unique formula should be established for every 
subject (18), while others propose not correcting the QT, but simply reporting the heart 
rate at which it was recorded (19). These suggestions could help improve accuracy and 
standardize research studies, but at a prohibitive cost of convenience to the clinician. On 
the other hand, Bednar et al (10) point out that in at least two studies using the QTc 
interval (20, 21), several different correction formulas yielded comparable results. 
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Apart from the method of correction for heart rate, other inconsistencies plague 
studies that use the QTc interval. Measuring the QT itself can be difficult when the 
presence of a U wave makes it unclear where the end of the T-wave lies (14, 15, 22), and 
results are difficult to compare across studies when different leads are used from one 
study to another (different leads on a 12-lead ECG show differing values of QTc, though 
this difference is most pronounced in subjects with myocardial infarction (23)), or when 
some studies use manual measurements while others rely on machines. Studies of QTc 
intervals derived from Holter monitoring should not be compared with studies that used 
standard 12-lead ECGs, as Holter measurements tend to be significantly different from 
12-leads (24). The QTc relationship changes over several minutes while heart rate is 
changing, such that measurements taken during a change in heart rate show a falsely 
elevated QTc (22). 
Many physiologic factors influence the QTc, such that to speak of a patient’s QTc 
is rather like speaking of his glucose level - a single value is of limited utility. QTc itself 
varies by gender, though not before puberty (14, 25). A diurnal variation has been 
demonstrated in adults (26, 27). Psychopathology itself may influence the interval, 
through changes in autonomic tone that can alter parasympathetic input to the heart (28). 
Many other confounders, including comorbidities and electrolyte disturbances, have been 
identified (10). Studies do not necessarily take these factors into account, and it can be 
unclear whether changes in the QTc can be ascribed to the intervention being studied, a 
confounder, or just physiologic variation. 
With respect to diurnal variation in particular, drug studies have sometimes 
downplayed the significance of drug-induced QTc prolongation by pointing out the large 
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diurnal variations in QTc that have been documented in adults. A study of 21 healthy 
men who had undergone Holter monitoring found an average daily variation of 95 ± 20 
msec (29). A retrospective study of 84 men and women participating in 11 unrelated 
pharmaceutical studies found variations between 7.0% below and 7.1% above an 8 A.M. 
baseline QTc (only unmedicated ECGs were examined; also, this study did not report 
using Holter monitor data) (26). Another study of 20 healthy men found that a manual 
measure of QTc varied over 24 hours of Holter monitoring by a mean of 76 ± 19 msec 
(range, 35 to 108 msec) (27). The authors of a study of the drug sertindole, which was 
removed from the market for QTc prolongation, argued that the 19.7-msec increase they 
found was not clinically significant because it fell within normal diurnal variation (30). 
A rejoinder to this argument, however, might be that since people have different 
baselines and differing rates of metabolism of medications, and because studies are so 
unstandardized that a typical patient will not necessarily be comparable to study subjects, 
any tendency to cause QTc prolongation by a drug is potentially hazardous. This appears 
to be the FDA’s position, which has required warning labels for drugs that prolong the 
QTc in this range. Caution would appear to be doubly warranted in children for the 
reason that data about possible diurnal QTc variation in healthy pediatric patients are 
lacking. (No studies could be found in the literature as of this writing.) Because the 
underlying causes of QTc variability throughout the day are poorly understood, it is 
difficult to speculate as to variability in children in the absence of actual data, so this 
phenomenon should not be resorted to as a reason to be unconcerned by increases in 
children. 

Clinicians often rely upon automated, machined-generated measurements of the 
QTc as a quick check on whether it is prolonged. However, manual measurement is 
considered much more accurate (11, 22, 31, 32). There are several reasons for this: the T- 
U wave transition can be ambiguous and may be misjudged by a computer; the QT may 
vary from lead to lead; and technical factors such as paper speed may affect sensitivity 
(32). Malik and Camm (22) discuss these phenomena in detail and provide dramatic 
examples of automated measurement inaccuracy; in two cases, the computer 
overestimated QTc by over 100 msec in the presence of physiologic U waves. Anderson 
et al (11) provide separate guidelines for large versus small U waves, recommending that 
the former be included and the latter excluded in QT measurement. A study examining a 
family with congenital LQTS compared automated measurements to those obtained with 
a manual method that involved measuring all twelve leads, and found that six of twenty- 
two subjects would have been misclassified by relying on the computer’s diagnostic 
interpretation. Although the computer’s QTc measurements agreed well with the manual 
measurements in this study, the authors strongly recommended manual measurement of 
the QTc, partly because the ECGs of the family they studied displayed unusually clear- 
cut T waves that may have aided computer recognition (31). 
Guidelines for measuring the QTc in pharmaceutical studies have been put 
forward by a group of experts on congenital LQTS, which include recommendations to 
measure the interval manually during peak plasma drug concentration, and to average the 
results of 3 to 5 heartbeats (11). Once a measurement is available, there are discrepancies 
amongst studies regarding whether QTc changes are reported as maximum or mean 
changes from the subject’s personal baseline (usually only one point, which some studies 
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do not check at all), or as a value compared to an arbitrary “abnormal” cutoff. This 
cutoff varies greatly in the literature. An extensive review of many reported instances of 
TP by Bednar et al (10) concluded that there was substantially greater risk of this 
arrhythmia only above a QTc of 500 msec. A review of the effects of psychotropic 
medications in children (33) used 440 msec as a cutoff for concern, as have a number of 
other workers (24, 26, 27, 34). A study of 158 children aged 1-15 years yielded 
suggested values of under 440 msec as normal, 440-460 as borderline, and 460 as 
prolonged in this age group (14). Several studies of subjects with congenital LQTS have 
provided more insight into values of concern in that population (31, 35, 36). In any case, 
it is unclear which method of comparison - change from personal baseline or difference 
with respect to an abnormal value - is the more predictive of cardiac adverse events. The 
Committee for Proprietary Medicinal Products (37) states that an individual QTc 
prolongation of 60 msec or more put subjects at risk of arrythmias. The authors of a 
study demonstrating diurnal variation in adults reviewed the literature and suggested that 
drug-related prolongation be considered clinically significant only if more than 5% of 
subjects had QTc intervals over 500 msec, or if any individual had a QTc prolongation by 
> 75 msec over baseline (27). It should be borne in mind that many studies of QTc 
prolongation and cardiac risk examined adults with heart disease, and this may not be 
generalizable to healthy children receiving psychotropic medications. 
There are other problems with interpreting QTc study results. Dosing of 
medications and their schedules varies from study to study, though this problem is not 
unique to QTc research. In real life, patients do not always take only one drug at a time; 
interactions are crucial to consider, and many adverse-event reports describe patients who 
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were taking more than one medication. The sensitivity and specificity of QTc 
prolongation for arrhythmia are unknown (13). For these reasons, it is as yet impossible 
to use the QTc to accurately predict risk of TP or sudden death for individual patients or 
with specific agents (38). A fuller discussion of these issues can be found in Bednar et al 
(10), which includes a table of proposed QTc correction formulas, and Labellarte et al 
(39), which is specific to pediatrics. 
In summary, owing to a lack of data in even adult studies, there are substantial 
gaps in our knowledge of the phenomenology of QTc prolongation by psychotropic 
medications. Flowever, the fact remains that prolongation is known to be associated with 
TP and sudden death, particularly prolongation > 500 msec. Diurnal variation has not 
been studied in the pediatric population, and prolongations in children should not be 
discounted for that reason. It would seem that, until better measures or measurement 
techniques are developed, the clinician would do well to exercise caution in the face of a 
prolonged QTc when using psychoactive medications in children. Details on worrisome 
ECG changes and recommendations for monitoring will be provided below. 
Effects of psychotropic drugs on the QTc interval in pediatric patients 
Several groups of psychiatric medications in children are of especial interest with 
regards to prolongation of the QTc interval. These are the antipsychotics, both atypical 
and typical, the alpha-agonists, and the tricyclic antidepressants. 
Antipsychotics: atypical agents 
Risperidone (Risperdal) is an atypical antipsychotic approved in 1994 and used to treat 
bipolar disorder, conduct disorder, pervasive development disorder, psychotic and tic 
disorders. Reports of adverse cardiac events are few, and there appear to be none in 
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children apart from several episodes of QTc prolongation. A toddler being treated with 
therapeutic doses of risperidone for severe autism developed persistent QTc prolongation 
as well as tachycardia (40). A 7-year-old boy developed central nervous system 
abnormalities after only one therapeutic dose; the symptoms worsened after a second 
dose, and a QTc of 460 msec was noted (41). A sudden death occurred in a 34-year-old 
woman treated with therapeutic doses who developed a QTc interval of 480 msec (42); 
she was being treated concurrently with amantadine and haloperidol. Risperidone in 
overdose in adults has been reported to cause prolonged QRS and QTc (43, 44) as well as 
isolated sinus tachycardia (45, 46) and in some cases no ECG abnormalities (47). There 
have been very few reported cases of pediatric risperidone overdose. A 3-year-old boy 
following an accidental 4 mg ingestion was found to have extrapyramidal symptoms, but 
no ECG abnormalities (48). None of the pediatric poison-control cases reviewed by 
Catalano et al (49) mentioned QTc abnormalities, and in the case reported in that paper - 
a fifteen-year-old girl who ingested 110 mg - only sinus tachycardia was evident on 
ECG. However, in an accompanying review of adult overdose reports, three of seven 
adult patients developed QTc prolongation (49). Another review of 48 overdose cases 
found increased QTc in five patients (50). Evidently, QTc prolongation is a possibility in 
risperidone-treated patients of all ages, not only in overdose but also in therapeutic 
dosage in certain patients. However, it appears to be a rare event. 
Olanzapine (Zyprexa), along with risperidone, is one of the most widely- 
researched atypical neuroleptics in pediatric psychiatry(51). Its influence on the QTc has 
been scrutinized in a number of studies and case reports. In Czekalla et al’s (52) complex 
analysis of four studies of olanzapine, the ECG of 2700 patients (mean age 38 years. 
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ranging from 18 to 86) revealed average prolongation by 8.44 msec from baseline in one 
study subgroup, with shortening by 7.83 msec in another study’s subgroup and no change 
in the remaining eight subgroups. Furthermore, the incidence of prolongation over 450 
msec was no higher in treated groups than it was at baseline. The authors concluded that 
QTc prolongation contributing to fatal arrhythmias does not appear to be a concern in 
olanzapine-treated patients. A study of seven psychoactive medications and their effects 
on the HERG potassium channel found that olanzapine was the most selective of the 
seven for dopamine and serotonin receptor binding relative to FIERG potassium channel 
affinity, suggesting it would have a lesser propensity to block the channel and lead to 
QTc prolongation (5). However, there has been a report of QTc prolongation, from 412 
to 485 msec, in a 28-year-old woman receiving higher doses (40 mg/day) than most of 
the ones studied in the above reviews (20 mg/day) (53). PR prolongation and first-degree 
heart block have also been reported (54). 
Overdose experience with olanzapine is modest but includes a number of 
pediatric cases. As reviewed in Catalano et al (55), lethargy and tachycardia are frequent 
and prominent symptoms, but not other electrocardiographic abnormalities. The pediatric 
presentation is dominated by these CNS abnormalities and is treated supportively. 
Several other cases have been reported without information about ECG intervals; CNS 
toxicity and tachycardia were prominent (56-58). Adult overdoses sometimes mimic 
opioid overdose, and have featured tachycardia and CNS toxicity, generally without QTc 
prolongation (59-63). At least two overdose deaths have been reported, as reviewed in 
Bums’ (50) review of 21 overdose cases. Searches of the literature using the strategies 
described earlier reveal no reports of pediatric or adult sudden death, TP, or arrhythmia 
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associated with the use of olanzapine. A Canadian Adverse Drug Reaction report, 
however, named olanzapine as a suspect in three reports of fatal arrhythmia, one of which 
involved several coingestants, and one case of QT prolongation, which involved the 
coingestants quetiapine and valproate (64). On balance, it would appear that evidence for 
QTc prolongation by olanzapine is, at best, equivocal, and that the drug is safer than other 
antipsychotics in this regard, at least in relatively low doses. 
Quetiapine (Seroquel), introduced in 1997, is an atypical antipsychotic similar to 
clozapine. A study in ten adolescents (65) found a small increase in heart rate; a common 
adverse effect was postural tachycardia. No subject’s QTc rose above 500 msec, or by 
more than 60 msec from baseline; no information was provided on whether any subject’s 
QTc exceeded 440 msec. Another open-label study of adolescents (51) found no changes 
in the PR interval, the QTc interval, or the QRS interval after eight weeks of quetiapine, 
though a small mean increase in heart rate and blood pressure were noted. These results 
are somewhat encouraging, but total only 25 subjects, all of whom are adolescents. 
There is still very little information on the effects of quetiapine in younger children, and 
no large-scale studies. 
There are a few reports of pediatric quetiapine overdose. One case occurred in a 
15-year-old girl (66), and another in an 11-year-old girl (67). The 15-year-old developed 
systemic symptoms which included tachycardia up to 188 bpm, while an ECG six hours 
post-ingestion found a QTc of 437 and a heart rate of 97. No cardiotoxicity was noted in 
the case of the 11-year-old. Bums reviewed adult overdoses and found QTc prolongation 
in only one of 216 cases (50). A case reviewed in Catalano (66) reported an increased 
QTc, after a ingestion of 9600 mg of quetiapine in a 19-year-old male. The QTc rose to 
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710 and resolved after a day (68). He, too, was tachycardic, an effect that is noted in the 
other reported overdoses. One adult death has been reported in association with an 
adverse reaction to quetiapine, but no details were available (69). No pediatric deaths 
after solely quetiapine ingestion, either in therapeutic or toxic doses, have been reported 
to date. 
Ziprasidone (Geodon) is a relatively new atypical antipsychotic that is effective in 
the treatment of positive and negative symptoms of schizophrenia and schizoaffective 
disorder (70-72). It is a benzosothiasol, chemically unrelated to phenothiazines or 
butyrophenones, and has a strong affinity for serotonin 5HT2a and dopamine D2 
receptors (73), and a lesser affinity for several other receptors (74). It is valued for its 
superior side effect profile, including a lesser tendency to cause weight gain (75). It has 
been under close scrutiny by the FDA before and since its approval in 2001 owing to its 
propensity to prolong the QTc interval more than many other atypicals. The mechanism 
of this prolongation is likely to involve blockade of the cardiac HERG potassium 
channel, although a study found that it was found to be more selective for two of its 
therapeutic receptors relative to HERG than were thioridazine, pimozide, and sertindole 
(5). A placebo-controlled study by the manufacturer found prolongation of 10 msec 
compared with placebo (76). Another study by the manufacturer. Study 054, compared 
the QTc prolongation by ziprasidone to that caused by other drugs, as well as to the 
patients’ own baselines; this study did not include a placebo control. The group taking 
ziprasidone consisted of 25 men (mean age, 38.6 years, range 22-58 years) and 10 
women (mean age 36.1 years, range 20-47 years) with baseline QTc < 450 msec (Bazett- 
corrected). 33 members of this group were eventually titrated to maximal doses of 160 
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mg/day (gender of two missing patients unspecified). With respect to patients’ own 
changes from baseline, of those 33, the QTc increased by > 30 msec in 21 subjects 
(64%), by > 60 msec in 7 subjects (21%), and by > 75 msec in one subject (3%) (patients 
with greater changes were also counted as falling into groups of lesser change)(77)A. The 
mean absolute increase from baseline in QTc was 20.6 msec (5%). With respect to other 
drugs, the study found that ziprasidone prolonged the QTc interval 9 to 14 msec longer 
than did risperidone, olanzapine, haloperidol, and quetiapine, but 14 msec less than did 
thioridazine (76). An FDA reviewer concluded the effect was concentration-dependent 
(77). Intramuscular administration of ziprasidone was found to increase the QTc almost 
the same amount as haloperidol causes. The manufacturer also reported that sudden 
deaths had occurred in patients taking therapeutic doses, but that the number of deaths 
did not exceed that of other drugs (76). Keck et al (78)studied 131 adults with bipolar 
mania taking doses from 80-160 mg/day and found an 11-msec mean increase of the QTc 
over baseline. 66 patients assigned to placebo were also analyzed, but mean QTc values 
of the two groups are not reported. A review in 2001 found no overdose deaths, TP, or 
excess of sudden deaths (79). Searches of the literature using the strategies described 
earlier reveal no reports of sudden death or TP associated with the use of ziprasidone in 
either adults or children. 
Only a few studies have examined the safety and efficacy of ziprasidone in 
pediatric subjects. A double-blind, placebo-controlled study of 28 pediatric patients with 
Tourette's syndrome treated with ziprasidone found no clinically significant changes in 
ECG parameters during treatment as compared with baseline (80). An open-label trial in 
A Page accessed March 2004. 
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8 adolescent boys found an increase in QTc of 17. 3 ± 28.6 msec (81)A. A study of the 
use of ziprasidone in 12 patients between the ages of 8 and 20 found no clinical cardiac 
effects; however, beyond a baseline pretreatment ECG, no ECG testing was performed 
(82). A chart review of thirteen children found a 19-msec prolongation in the one child 
for whom both baseline and follow-up ECG data were available (83). 
Experience with overdose is also limited. In the case of a 17-month-old girl who 
ingested 400 mg, transient tachycardia to 240 bpm, developed with a QTc of 480 msec 
and BP of 121/60. The child recovered after an uneventful day of monitoring. The two 
other patients in the same series, who were adults, developed QTc prolongation to 459 
msec (with cocaine and heroin coingestion) and 638 msec (with quetiapine coingestion; it 
fell to 486 msec after magnesium sulfate treatment) (84). One overdose with ziprasidone, 
bupropion, and benzodiazepines was taken by a 17-year-old boy who developed QTc 
prolongation to a maximum of 480 msec (85). A 50-year-old man ingested 3120 mg and 
his QTc increased to 490, with nonspecific T-wave abnormalities peaking at 6 hours post¬ 
ingestion (86). Another case involved a 38-year-old woman who had taken 4020 mg of 
ziprasidone; she was also on quetiapine, gabapentin, venlafaxine, metformin, rofecoxib, 
and pravastatin but denied ingestions of these above her normal therapeutic dose. At 6 
hours post ingestion, her QTc interval was 445, and her QRS duration was 111 (87). 
Clozapine (Clozaril) first became available in 1989. It is the prototype atypical 
antipsychotic, but its use is limited to second-line therapy, owing to its propensity to 
cause fatal agranulocytosis (88), among other serious adverse effects including 
pulmonary embolism (89) and myocarditis (88, 90). Dose-dependent QTc prolongation 
has been demonstrated in feline hearts (91) and in human adults (92), in addition to other 
A Abstract received January 2004. 

17 
ECG abnormalities. One patient who had a QTc of 624 on clozapine improved to 504 
msec after being switched to olanzapine (93). A 44-year-old man developed atrial and 
ventricular fibrillation after two weeks of clozapine therapy (94). Atrial fibrillation in a 
69-year-old man has been reported (95). In children and adolescents, tachycardia has 
been noted; it is not known if this study specifically addressed the QTc parameter (96). 
There are numerous reports of both fatal and nonfatal overdoses of clozapine, and 
there is evidence of increased risk of sudden death in patients taking therapeutic doses of 
clozapine compared with patients taking other psychiatric medications (88, 97). 
Sertindole (Serdolect) is an atypical antipsychotic with a checkered past. When 
introduced in 1996, it was hailed as well-tolerated and efficacious in treating positive and 
negative symptoms of schizophrenia without extrapyramidal or other serious side effects. 
Unfortunately, reports of sudden death led to its removal from the market by the 
manufacturer in December 1998. A propensity to prolong the QT interval was known 
before the drug’s large-scale introduction, but this prolongation was not as strongly 
associated with arrhythmias as might be expected (30, 98). Prolongation has been 
demonstrated in numerous studies and is dose-dependent (30, 99, 100). The mechanism 
of prolongation involves high-affinity antagonism of the HERG potassium channel (101). 
In a study of seven psychoactive drugs, sertindole was one of three - the others being 
pimozide and thioridazine - found to have very little selectivity of dopamine and 
serotonin blockade compared with affinity for EfERG (5). The usage of sertindole 
remains controversial, as the clinical significance of prolongation is not known with 
certainty; for example, though one study demonstrated an increase in QTc during 
sertindole treatment as compared with treatment with a wide variety of other 
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antipsychotics, the authors argued that this increase is not clinically significant, in part 
because in 19.7 msec is less than the diurnal rate variation in normal subjects (30). 
AripiprazoleA (Abilify) is a recently-approved atypical antipsychotic with a 
unique pharmacologic mechanism called dopamine system stabilization; it has fewer 
adverse effects than many other antipsychotics (102). Clinically significant QTc 
prolongation has not been noted in any of several studies of adults (102-105). No studies 
of children specifically examining the QTc interval have been published. Kowatch and 
DelBello (106) recommend that clinicians be on the lookout for interactions with the 
cytochrome P450 systems 3A4 and 2D6 when prescribing this medication in children and 
adolescents with bipolar disorder. 
Antipsychotics: traditional agents 
Phenothiazines: thioridazine and chlorpromazine. 
Among the antipsychotics, thioridazine (Mellaril) has the greatest and best- 
documented propensity to prolong the QTc interval, due to its blockade of the delayed 
rectifier potassium channel (5, 107). It was this drug that was implicated in the first 
reports of sudden arrhythmic death on antipsychotics in 1963 (108). Since then, there 
have been numerous reports of TP (109, 110), QTc prolongation (111) in both therapeutic 
and overdoses (112), and an excess of sudden deaths (107, 113) and cardiotoxicity in 
overdose (114) as compared with other antipsychotics. QTc prolongation is dose- 
dependent (115-117). The mean increase in QTc has been measured at 33 to 35.8 msec, 
the longest of all the antipsychotics with the exception of intravenous droperidol (118). 
223 cases of overdose with thioridazine have been summarized by Le Blaye et al 
(119), of which 23 occurred in children aged 12 years and under. 68 patients had ECG 
A Search completed October 2003. 
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changes, which included ventricular arrhythmias; third-degree block, especially in 
association with alcohol coingestion; and bundle branch block. These patients were more 
likely to have ingested higher doses than patients who did not have ECG changes. 17 of 
223 patients had QT prolongation. TP was reported in only one case, that of an overdose, 
in which the patient had previously received amiodarone. 
Thioridazine owes some of its electrocardiographic effects to its active metabolite 
mesoridazine (also sold separately as Serentil). Both drugs’ package inserts carry an 
FDA black-box warning - the most serious warning the agency can issue in a drug’s 
labeling (120)- for dose-dependent prolongation of the QTc interval. Though it has been 
studied in children and adolescents for conduct disorder and schizophrenia, and is 
sometimes used in this population to treat psychosis, mania, aggression, agitation, autism, 
and self-injury (121), thioridazine is mainly indicated as third-line therapy in 
schizophrenic patients. However, some investigators have questioned the adequacy of 
the data to support avoiding its usage exclusively, given the propensity of other 
phenothiazines to prolong the QTc as well (122, 123). 
Chlorpromazine (Thorazine), like thioridazine, is a phenothiazine, and as such 
may have the potential to cause ventricular arrhythmias including TP. Phenothiazines are 
thought to have their effect on the ECG by a mechanism similar to that of quinidine, 
which inhibits the delayed potassium rectifier current in myocytes and prolongs 
repolarization, as represented by the QT interval (124). Chlorpromazine has been shown 
to inhibit HERG potassium channels (125). It can do this at therapeutic dosages, in 
addition to causing other changes on the ECG (124), though it is unclear whether the 
effect is dose-dependent. Cases of TP have also been reported. One case occurred in a 
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female adult patient after long-term treatment, featuring a QTc prolongation to an 
astonishing 0.81 seconds; the TP resolved with discontinuation of the drug, and, 
interestingly, resumed when the drug was resumed (126). A review of the literature 
published in 2001 found only four reports of chlorpromazine-induced TP (including the 
aforementioned case), as well as several more ventricular arrhythmias, most of which 
included QTc prolongation. Electrolyte imbalances were noted in some cases, including 
hypokalemia, hypocalcemia, hyponatremia, and hypomagnesemia. There is a distinct 
female preponderance, which fits well with the longer baseline QTc in women. It is 
unclear whether this effect is relevant in children, as it is hypothesized that estrogen is 
responsible for the sex differences. None of these cases of chlorpromazine-induced 
arrhythmia occurred in children, and none could be found in the literature as of this 
writing. 
Butyrophenones: haloperidol and droperidol 
Like haloperidol (Haldol), droperidol (Inapsine) is an older typical butyrophenone 
antipsychotic. In children it is often used for rapid sedation of agitated patients in the 
acute setting (127, 128); it is not intended to be taken over the long term (129). Unlike 
haloperidol, however, droperidol has recently earned an FDA black-box warning similar 
to that of thioridazine about the potential for arrhythmia. The manufacturer reports that 
QTc prolongation, TP, and deaths have occurred in doses at and even below the 
therapeutic range, and recommends the droperidol be considered a second-line drug and, 
and avoided in patients with long QT on initial ECG screen and patients with a 
suggestive personal or family cardiac history (130). These recommendations are similar 
to those offered by Wooltorton (131). Another study has demonstrated a dose-dependent 
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increase in QTc with intravenous droperidol (132). A 1996 review of cases of 
conduction disturbances in critically ill patients treated with droperidol concluded that the 
risk of QTc prolongation and arrhythmia was real, and that ECG monitoring at baseline 
and treatment should be done, that baseline serum magnesium and potassium should be 
checked and corrected, and that a 25% increase in the QTc after receiving droperidol is 
grounds for discontinuation of treatment (133). 
Despite the black-box warning, however, recommendations to avoid droperidol 
altogether have been controversial. Some authors argue that it is unclear that the deaths 
referred to in the warning were related to droperidol, that no risk-benefit assessments 
have been performed analogous to those performed after thioridazine was singled out for 
danger, and that studies finding an increased QT interval were often done in very large 
doses (134). 
Haloperidol has a somewhat less tarnished reputation in terms of cardiac effects 
than its sister butyrophenone, droperidol. One of the oldest antipsychotics, it is 
prescribed to children for the management of disorders including hyperactivity, autism, 
Tourette's syndrome, and obsessive-compulsive disorder. It is also used in the 
management of acute severe aggression, often as an intramuscular administration. 
Although cardiotoxicity is not common - extrapyramidal effects are much more prevalent 
and important - cardiac effects have been reported. There are a number of reports of TP 
and increased QTc in critically ill adults being treated with haloperidol. Cardiotoxicity 
tended not to become apparent below 1000 mg ingestions - hundreds of times the 
recommended dose - but in some individuals even therapeutic doses caused the problem. 
Many such cases were presaged by an elevated QTc, but in at least one report of a 66- 
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year-old woman who developed TP on therapeutic dose, this was not the case (135). 
Another woman, aged 41, developed TP with a QTc of 610 msec only 55 minutes after 
receiving intravenous haloperidol (136). A crossover study in adults found no QTc 
prolongation compared to baseline during two weeks of treatment with haloperidol (137). 
A double-crossover study of 40 adult patients with Tourette’s syndrome, in which 
haloperidol and pimozide were compared, found no QTc prolongation in the haloperidol- 
treated group (and only clinically nonsignificant prolongation in the pimozide group) 
(138). One series found an association of prolonged QTc and TP in adult intensive-care 
unit patients with pre-existing heart disease (139). 
As of this writing, there have been no reported instances of TP or sudden deaths 
occurring in children treated with haloperidol. Pediatric overdosages have been reported, 
in which CNS symptoms dominate the presentation; in one series, in which eight children 
had ECGs done upon admission to the hospital after accidental haloperidol ingestion, two 
were said to have had a prolonged QT interval, but the degree of prolongation was not 
specified (140). Bradycardia, possibly secondary to drug-induced hypothermia, has been 
also reported in overdose involving 29-month-old and 11-month-old siblings (141). 
Pimozide (Orap), a diphenylbutylpiperidine, is generally used as an alternative to 
haloperidol in treating Tourette’s syndrome. It has been shown to be more effective than 
placebo in tic disorders, with fewer side effects than halopendol (142). However, it too 
is associated with arrhythmias and dose-dependent QTc prolongation (138, 143, 144), 
probably because of its HERG potassium-channel blocking properties (5, 145). Sudden 
death at doses over 20 mg/day has been reported (146, 147). Most authorities 
recommend a baseline ECG before starting treatment with pimozide; while dosages are 
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being adjusted, avoiding dosage increases above a QTc that is 470 msec or more than 
25% above baseline (148); at steady-state; and then every year (149). As with other 
drugs metabolized by the cytochrome P450 system, caution should also be exercised with 
regards to polypharmacy when prescribing pimozide, particularly with the macrolides: at 
least two sudden deaths have been reported in young adult subjects taking pimozide and 
clarithromycin at the same time (143). TP has been reported in a case of pimozide 
overdose in a 53-year-old woman (150). 
There have been no case reports of sudden death or TP in children taking 
pimozide. Controlled studies of children have been few, and though at least one found no 
ECG abnormalities, this result is hardly reassuring in light of the small numbers of 
children studied. One open-label pilot study of eight boys between the ages of four and 
eight treated for three weeks with pimozide reported that ECG parameters remained 
within normal limits during weekly ECGs, but no details were given (151). 
Alpha agonists 
Originally developed as antihypertensives, the alpha agonists clonidine (Catapres) 
and guanfacine (Tenex) are being used to an increasing extent in psychiatry owing to 
their effects on central noradrenergic systems, and to an indirect extent the serotonergic 
and dopaminergic systems. Popular indications include second-line therapy for attention 
deficit-hyperactivity disorder and tic disorders after stimulants, tricyclics, and/or 
bupropion have failed, or in combination with methylphenidate (152). However, there are 
no FDA approvals for psychiatric indications, and data on the use of alpha agonists in 
children tends to come from uncontrolled studies, or controlled studies with a small 
number of subjects (152, 153). Although clonidine has been noted to produce ECG 
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changes, these are generally not considered dangerous in children without preexisting 
cardiac disease. There is more information on clonidine than on guanfacine in the 
literature, but it would be prudent to presume similar effects in guanfacine until more 
specific information is available. 
That the alpha agonists should affect the heart follows from their mechanism of 
action. All adrenergic receptors inhibit the opening of voltage-gated Ca channels and 
activate K channels (154); alpha agonists strengthen such actions. The first reported 
episode of cardiotoxicity occurred in a 22-year-old woman, who experienced transient 
high-grade atrioventricular block in association with toxic levels of clonidine (155). 
Children taking clonidine either alone or in combination with other psychiatric 
medications have been reported to develop asymptomatic ECG abnormalities when the 
dosage was increased. These reverted with reduction of dosage, suggesting a threshold 
effect. Changes included sinus bradycardia, supraventricular premature complexes, 
intraventricular conduction delay, junctional escape ST and T-wave abnormalities, 
anterior ischemic changes, atrioventricular block, and QTc intervals ranging from 409 to 
425 (2, 156, 157). The clinical significance of these changes is unclear, but are generally 
similar to expected electrophysiologic changes in adults (158). ECG changes reported in 
a child who was symptomatic with fatigue and sedation included hypotension and 
bradycardia, ST elevation, early repolarization, and junctional escape rhythm (2). 
A retrospective examination of 42 children on either clonidine alone or clonidine 
plus a stimulant found that the ECG was as likely to normalize as to become abnormal 
during treatment, and thus that ECG changes were more likely attributable to normal 
changes in ECG over time, rather than to an effect of clonidine (159). The authors found 
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no prolongation of QTc over 440 msec. This finding should be inteipreted with caution 
due to the small size of the study and inconsistencies in the time of day the ECGs were 
taken, but it suggests that studies purporting to find an effect of medications on the ECG 
should be viewed with caution in the absence of pretreatment ECGs. Unfortunately, little 
is known about the extent or causes of normal ECG variability in children, and the 
authors warn that it is difficult to disentangle drug-induced ECG changes from other 
causes of variation. They also point out that the lack of effect in this group does not rule 
out the possibility that some children may be highly affected. They call for replication 
with Holter monitoiing, with ECGs at the same time of day, and with the same 
relationship to the time the medication was taken. 
Clonidine overdose in adolescents has been reported to lead to labile blood 
pressure and sinus tachycardia without other ECG abnormalities, in the case of a 16-year- 
old girl who took approximately 6 mg clonidine; and bradycardia, in the case of an 18- 
year-old man who took 4 mg clonidine along with alcohol (160). Hypotension and 
bradycardia have been noted in many other pediatric overdoses (160-162). The only 
reported case of guanfacine overdose in a child (163) occurred in a two-year-old who 
ingested 4 mg; the only adverse event was a drop in blood pressure to 58 mm Hg systolic 
some hours after ingestion. This resolved without incident. 
Abrupt discontinuation of clonidine leads to a well-recognized spectrum of 
cardiovascular and autonomic effects, including ST segment changes, QTc prolongation, 
and serious ventricular arrhythmia in adults (164). Sinus tachycardia and tachypnea were 
reported in a 10-year-old girl who missed a dose (2). 
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An association of clonidine or of clonidine and methylphenidate (Ritalin) with 
sudden death has been noted in at least four cases, but in each case there were 
circumstances making it difficult to ascribe the deaths to clonidine (165). In one case, 
blood analysis could detect neither drug, in two others, cardiac malformations were 
found, and in a third, death was blamed upon intentional fluoxetine overdose (165, 166). 
Recommendations to obtain a cardiac history and baseline and treatment ECGs have been 
controversial, owing to the uncertain benefit of these time-consuming measures in light 
of the rarity and uncertain causation of the deaths (158). Some experts feel that clonidine 
or clonidine plus methylphenidate are safe, while others warn against routine use of this 
combination (165). 
Tricylic antidepressants 
Tricyclic antidepressants (TCAs), in use for over 50 years, have long been known 
to prolong the QTc interval in both adults and children. The most commonly used drugs 
of this class in children are imipramine, desipramine, nortriptyline, amitryptiline, and 
clomipramine. They are used for a variety of indications, including attention deficit- 
hyperactivity disorder, obsessive-compulsive disorder (clomipramine only), and enuresis. 
The primary noradrenergic mechanisms of TCAs involve blockade of norepinephrine 
reuptake, as well as binding to presynaptic alpha-2 receptors and increasing 
norepinephrine release; autonomic tone increases and raises the blood pressure and heart 
rate. Tricyclics also bind to and activate the postsynaptic alpha-1 receptor. 
Clomipramine has a similar uptake-blocking and postsynaptic-activating effects in the 
serotonergic system. Their anticholinergic side effects, which are more pronounced in 
the tertiary amines, can be attributed to their antagonism of muscarinic receptors; 

27 
however, these effects are less common in children than they are in adults. Finally, they 
block histaminic receptors. This blunderbuss nonspecificity is not confined to the central 
nervous system, as the TCAs’ lipophilic structure allow for body-wide distribution. 
Cardiac side effects caused by therapeutic levels of TCAs include rise in blood pressure, 
increases in heart rate (by 20-25%), and in the ECG intervals PR (by 5-10%), QRS (by 7- 
25%), and QTc (by 3-10%) (167). These changes occur due to increased anticholinergic 
and noradrenergic tone in the cardiac conduction system, with inhibition of sodium influx 
specifically responsible for slowing propagation of depolarization and widening the QRS 
(168). Dose-response relationships are weak at low doses, but more evident at high doses 
or serum levels (169). Wilens et al’s (33) detailed analysis of ECG changes found that 
the tricyclic causing the greatest increase from baseline QTc is probably imipramine, 
while desipramine appears to cause higher rates of incomplete intraventricular 
conduction. The authors concluded that these changes are likely to be of only minor 
clinical significance. Desipramine has also been shown to reduce heart rate variability in 
children, a circumstance that in some circumstances can predispose to arrhythmia (170). 
TCAs, and particularly desipramine, have been associated with several sudden 
deaths in children and adolescents. A recent review of eight case reports (1) found that in 
six cases the child was taking desipramine, in one case imipramine and thioridazine, and 
in one case imipramine and dextroamphetamine. ECG data on these children prior to 
their deaths is scant, though one child reportedly had a QTc prolonged to 0.44-0.45 
(baseline was 0.40) seven to fourteen months before death. Exercise immediately 
preceded cardiac arrest in four and possibly five cases. A study in response to the latter 
finding examined 9 pediatric and 13 adult subjects on desipramine with exercise testing. 
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and found modest elevations in blood pressure and heart rate, as well as an episode of 
ventricular tachycardia in a 31-year-old (171). Another study which examined 23 
pediatric patients taking imipramine found no ventricular arrhythmias, supraventricular 
tachycardia, or atrioventricular conduction blocks during exercise testing (172). 
Desipramine was blamed in one death and imipramine in two others. One child had an 
abnormal coronary artery on autopsy. There was a family history of sudden deaths in 
young family members in the case of one child, and of other adverse cardiac events in the 
families of three others. The deaths were considered probably cardiac, but despite the 
TCAs’ known cardiac effects, reports of TP are rare (173-178). One author proposed a 
mechanism of “reversed adrenaline” to explain the sudden deaths, arguing that blockade 
of alpha-adrenoreceptor-mediated vasoconstriction from a sudden endogenous or 
parenteral adrenaline load could have caused hypotensive collapse (179). Overdose may 
have been involved in several cases in which elevated levels of drug were found in 
postmortem blood samples; however, these elevations may have been factitious owing to 
postmortem changes (1). Due to the preponderance of desipramine or pro-desipramine in 
the deaths, some debate has centered around the use of this drug, with at least one author 
calling for its discontinuation in pediatrics (180) and others arguing that evidence of 
excessive danger is weak (181). Though these concerns are longstanding (182), there 
appear to be insufficient data at present to conclude that one tricyclic is definitely more or 
less harmful than the others (183). Given the small number of reports and the many 
confounding factors in those that do exist, a definite increased risk of sudden death in 
children taking tricyclics has not been established. 
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It is not a matter of dispute, however, that TCAs are cardiotoxic to all age groups 
in overdose. Hypotension is the commonest effect, but prolongation of the PR, QRS, and 
QTc occurs as well, as do ventricular arrhythmias (168, 184). There has been some 
research into the best way to stratify patients according to risk. In one series, children 
who presented with seizures were found to have the longest QTc prolongations (185). 
QRS duration may be more helpful than serum levels in predicting severity; one study 
found that QRS duration exceeding 160 msec in adult overdose patients was a significant 
predictor for risk of ventricular arrhythmias over a wide range of serum levels (186). 
Treatment recommendation guidelines 
A number of authorities have proposed sets of treatment recommendations which, 
if followed carefully, should reduce or minimize the risk of conduction-velocity changes 
or arrhythmias in children taking antipsychotics, alpha agonists, and tricyclic 
antidepressants. Briefly, these children should receive a thorough screening visit with 
careful attention to history of symptoms possibly referrable to the heart, to family history, 
and to any other medications being taken; physical examination with vital signs; and 
baseline studies which, depending on the medication being considered, may include 
ECG, referral to a pediatric cardiologist, or laboratory measurements. Clinically 
significant changes in the EKG in children are generally felt to include the following: 
pulse < 60 or > 130 bpm, PR > 200 msec, QRS >120 msec or > 25% change from 
baseline, or QTc > 450 msec (167, 187) (440 msec is a more conservative red flag). QTc 
prolongation by > 60 msec should prompt concern (37), as should morphologic 
abnormalities such as T-wave inversions, U waves, or arrhythmias. Clinicians should be 
aware that these guidelines are not set in stone; for example. Moss (13) considers 460 

30 
msec to represent significant prolongation in children. Tables 1 and 2 provide an 
overview and a summary guideline, respectively, for current recommendations regarding 
ECG monitoring in pediatric psychopharmacology, and based on the literature reviewed 
and clinical experience. Table 3 summarizes relevant drug combinations of potential 
concern, as specifically pertaining to ECG safety. These tables should not be taken as 
definitive, but rather as guides, given that questions remain about the effects of these 
medications in pediatric patients. 
PROSPECTIVE STUDY: STATEMENT OF PURPOSE AND HYPOTHESIS 
The aims of this study were: (1) to assess the electrocardiographic (ECG) safety 
profile of low-dose ziprasidone (< 60 mg/day) among psychiatrically ill youths treated as 
outpatients for up to six months, and (2) to compare automated, machine-generated ECG 
parameters to those derived via manual measurement by a pediatric cardiologist blind to 
medication and dosage assignment. 
The null hypotheses were as follows: a) low-dose ziprasidone does not cause 
clinically significant ECG changes in pediatric patients, and b) manual and automated 
measurements of ECG parameters do not significantly differ. 
METHODS 
This was an open-label, prospective clinical trial of ziprasidone in pediatric patients 
diagnosed with Tourette’s syndrome (TS), obsessive-compulsive disorder (OCD), or a 
pervasive developmental disorder (PDD). Performed under an Investigational New Drug 
(IND) approval from the FDA in 1999 for the treatment of refractory cases, the study 
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took place in 2000. This study was designed by Andres Martin to examine the drug’s 
electrocardiographic safety profile in children and adolescents by using small doses and 
emphasizing close ECG monitoring. It was performed by Andres Martin and Lawrence 
Scahill, and by staff members under their supervision. All data were collated by Jennifer 
Blair. Statistical approach to data analysis was done by Andres Martin and Jennifer 
Blair. 
Subject Eligibility 
Male and female subjects aged 7 to 19 were eligible for participation in the study if they 
met the following inclusion criteria: (1) DSM-IV diagnosis of TS, OCD, or a PDD, based 
on a standard clinical evaluation and corroborated through appropriate structured 
diagnostic interviews, such as the child and adolescent version of the Schedule for 
Affective Disorders and Schizophrenia (K-SADS)(188), the Autism Diagnostic 
Interview-Revised (ADI-R)(189), or the Autism Diagnostic Observation Schedule 
(ADOS)(190, 191); (2) at least “moderate” symptomatic severity, as indicated by a 
clinical global impression (CGI) rating of >4 (192); (3) symptom severity score of > 1.5 
SD above clinically established norms in the primary outcome measure specific for the 
disorder (Yale Global Tic Severity Scale (YGTSS)(193), Children’s Yale-Brown 
Obsessive Compulsive Scale (Y-BOCS)(194), or Aberrant Behavior Checklist 
(ABC)(195-197); (4) evidence of failure on at least one atypical antipsychotic medication 
such as risperidone, as defined by either less than 30% symptom reduction in the primary 
outcome measure, and/or unacceptable side effects requiring drug discontinuation - 
weight gain in excess of 2 kg/month being the more common, and occurring in 6 of 20 
participants; and (5) at least 2 weeks since treatment with another neuroleptic was 
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discontinued (4 weeks for depot neuroleptics). In addition, subjects were required to 
have a mental age of at least three years. Intelligence was assessed in verbal children with 
the Wechsler Intelligence Schedule for Children-III (WISC-III)(198), and in nonverbal 
children with the Leiter International Performance Scales, Revised (199). The Vineland 
Adaptive Behavior Scales were used to assess adaptive functioning (200). Mental 
retardation was defined as WISC or Leiter IQ scores < 70, and Vineland adaptive scores 
in the deficient range. 
Subjects were required to weigh at least 20 kg and be free of major medical 
conditions such as heart disease, hypertension, liver or renal failure, pulmonary disease, 
or unstable seizure disorder identified by history, physical examination or laboratory 
tests, including ECG, at the screening visit. Baseline QTc interval was required to be < 
450 msec. Postmenarchal females required a negative serum human chorionic 
gonadotrophin test to rule out pregnancy. Concurrent psychotropic medication was 
exclusionary, except for previous selective serotonin reuptake inhibitor use in 4 subjects 
(fluoxetine in 3, sertraline in 1). 
All pediatric patients were enrolled through the Yale Child Study Center’s 
pediatric psychopharmacology clinic. As part of the IND from the FDA, adults were also 
to be enrolled in the study. After a full description of the study and of available treatment 
alternatives, subjects’ parents or caregivers (or, if adults, the subjects themselves) signed 
written informed consent. When feasible, informed assent was obtained from the patients 
themselves. The study and its consent documents were approved by the Yale University 
School of Medicine’s Institutional Review Board. 
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Study design and dosing schedule 
The trial was originally planned as a one-year, prospective, open-label design. On Day 1, 
subjects received 5 mg of ziprasidone to be taken at bedtime with food. The dose was 
raised by 5 mg every 4-6 days in the first month as tolerated, or to a target maximum of 
20 mg BID. After the first month, the dosage was raised or lowered according to clinical 
judgement. The low dosage, agreed upon with the FDA, was intended to emphasize 
safety and was to be a prelude to studies at higher clinical doses. See Table 4 for a 
sample dosing schedule. Subjects older than 18 years old were permitted to exceed it, 
and the highest dosage reached was 30 mg BID by one nineteen-year-old female. 
Primary caregivers administered all study medications in a divided morning and bedtime 
oral dosing schedule. A baseline, pre-medication electrocardiogram was obtained at the 
outset of the study, and repeated at weeks 1, 2, 3, 4, 6, 8, 12, and monthly thereafter. 
ECGs, except for several obtained off-site during patient vacations or other logistic 
conflicts, were obtained with a Hewlett Packard XLi PageWriter electrocardiographic 
machine at the pediatric cardiology laboratory at Yale-New Haven Children’s Hospital. 
Its ECG analysis program uses the Bazett formula (QT divided by the square root of the 
R-R interval) to calculate QTc values. Printouts of twelve-lead ECGs were sent to 
eResearch Technologies in Philadelphia, PA, where two technicians and a board-certified 
pediatric cardiologist performed manual measurements designed to obtain accurate and 
reliable QTc intervals. 
Data analysis 
Statistical analysis involved comparison of each subject’s baseline and peak values of 
manually-measured QTc intervals using paired t-tests. Results are reported as absolute 
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(msec) and relative (%) changes, are expressed as mean ± standard deviation (SD), and 
considered significant at p < 0.05. Pearson’s correlation coefficients were computed to 
compare ECG intervals derived through manual or automatic means, as well as the 
relationship between dose and QTc interval change. The kappa coefficient was used to 
evaluate the agreement between automated and manually-assessed QTc prolongation 
(using > 440 msec as cutoff). The chi-square test was used to compare the proportion of 
subjects in our study with prolongation to the proportion with prolongation in a study 
done by the manufacturer (see Table 8), with Fisher’s exact test used for cells whose 
value was 1. The SAS program was used for all calculations. 
RESULTS 
Subjects 
An adult patient enrolled under the same IND unexpectedly died during the course of the 
trial, of causes eventually deemed to be unrelated to ziprasidone. Pending autopsy results 
and a full postmortem investigation, the trial was discontinued, in close consultation with 
the Institutional Review Board at Yale as well as with representatives from the FDA. The 
specifics of this death are detailed in Scahill, Blair & Martin (2004, in preparation), and 
all clinical data of that individual (including ECG data) are not included as part of this 
report. 
Prior to the study’s premature discontinuation, 20 patients were enrolled, each of 
whom received at least a baseline and one follow-up ECG. Sixteen participants were 
boys, four girls; sixteen were Caucasian, three Hispanic, and one African-American; their 
mean age was 13.2 ± 3.0 years (range, 8 to 19). Nine subjects carried a primary 
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diagnosis of TS, four of OCD, and seven of PDD. One subject with OCD had a 
comorbid tic disorder, as did one with PDD; two with TS also had OCD, and one with 
PDD had both comorbid OCD and a tic disorder. Other secondary diagnoses included 
learning disorders, attention deficit-hyperactivity disorder, and oppositional-defiant 
disorder. Six of the seven children with PDD had mental retardation. 
Although clinical efficacy data were collected alongside the safety data, these are 
not reported here (Scahill et al, in preparation). When the study was prematurely 
discontinued, 20 subjects had been recruited out of a target number of 30, and each had 
been followed for, on average, fewer than six months out of a target duration of one year. 
Only the results of the ECG investigations are reported here. 
Subjects were treated with a mean ziprasidone dose of 30 ± 13 mg/day (range, 30 
to 60), and were followed for 4.6 ± 2.0 months (range, 0.7 to 6), during which a median 
of 9 ECGs were obtained per subject (range, 2 to 11). This yielded a total of 176 ECGs 
that were manually analyzed. 
Measurement methods 
A weak correlation between QTc prolongation and ziprasidone dose was detected 
when using automatically-derived values (r = 0.203, p < 0.01), but was no longer evident 
when using manually-calculated means (r = 0.159, p = 0.07). The two measurement 
methods were correlated with each other (r = 0.52, p < 0.0001), but as depicted in the 
scatterplot of Figure 1, many outliers were readily apparent, particularly around extremes 
of the value range. 
Among the 176 ECGs available for analysis, there were 134 (76%) for which both 
manual and automated measurements of QTc were obtained. In 17 (13%) of these, a 
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prolonged QTc (defined as > 440 msec) was detected by either automated or manual 
measurement. Among these, only 3 were considered prolonged by both manual and 
automated methods (percent agreement, 18%; k = 0.25), indicating only minimal 
improvement over the amount of agreement expected by chance alone (201). Using 
manual measurements as the gold standard, the machine’s sensitivity for prolongation 
was 25%, while its specificity was 95%. See Table 5. 
Electrocardiographic parameters (manual measurements) 
The mean QTc interval increase from the baseline to the peak value was 28 ± 26 
msec (representing a 7 ± 8 % increase). The maximum increase from baseline was 114 
msec. No patient’s QTc ever exceeded 500 msec; the highest observed value was 470 
msec. There were also statistically significant changes from baseline to peak values in 
heart rate and in the PR interval (p < 0.01 for each), but not in QRS complex width (p = 
0.87). These results are summarized in Table 6. Eight patients experienced QTc 
prolongations of > 440 msec while on ziprasidone; three of those had episodes > 450 
msec. See Table 7. A comparison of the number of subjects who experienced changes 
from baseline of > 30, 60, or 75 msec with the same result from the manufacturer’s study 
of ziprasidone is shown in Table 8. A chi-squared test found no significant difference 
between the number of subjects with prolongation in our study versus the manufacturer’s; 
this is represented on the table by the p value of the test results. 
DISCUSSION 
The part of this study concerned with measurement of the QTc found a poor 
agreement between methods in detecting QTc prolongation. In light of the likelihood that 
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clinicians often rely upon automatic numbers, this is concerning, as is the 25% sensitivity 
of the machine - indicating the machine “missed” 75% of prolongation “events” greater 
than or equal to 440 msec, although its high specificity suggests that when it detects 
prolongation, manual confirmation may not be necessary. The null hypothesis of no 
difference between the methods is rejected. It would seem necessary to advise - or 
remind - clinicians to mistrust the numbers that appear on an ECG printout, particularly 
the QTc. Again, this is not a new finding; many authors have discussed the inherent 
weaknesses of automated measurements of this interval (11, 22, 31, 32). Because manual 
measurement of the QTc trumps the software, psychiatrists who obtain ECGs would be 
well-advised to send them to an experienced cardiologist, who will be familiar with the 
careful methods of measurement that are delineated by, for example, Anderson (11) and 
Al-Khatib (38). The growing ease of electronic data transmission may make this simpler 
in the future, but at present many ECG machines are not linked to the Internet, and 
clinicians may need to make use of fax machines, at times sacrificing some precision 
along the way. 
With regards to QTc prolongation, this study demonstrates that treatment with 
ziprasidone is associated with increases over baseline of the QTc interval in children and 
adolescents. This increase is greater (mean, 28 ± 26 msec) than that demonstrated in 
studies of adults, which found a mean of 20.6 msec (76) or 11 msec (78) increases over 
baseline. It is consistent with another group’s demonstration of QTc prolongation from 
baseline by 17.3 msec in eight adolescent patients treated with ziprasidone (81). Apart 
from inherent difficulties in interpretation of the QTc, the study was limited by a small 
sample size, lack of placebo control (preventing comparisons with the manufacturer’s 
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finding in adults of a 10 msec increase versus placebo (76)), open-label design, 
unbalanced gender ratio, heterogenous ages and diagnoses, and premature 
discontinuation. Automated measurement data were lacking for some ECGs, which 
weakens our analysis of the differences between manual and automated measurements. 
Only one baseline ECG was obtained for each patient, which may or may not represent a 
true personal baseline. 
Despite these limitations, there are several reasons to be concerned by our study 
results. The mean increase among these 20 pediatric subjects is greater than a value 
which led the FDA to mandate a boldface warning in ziprasidone’s package labeling. 
Eight subjects experienced prolongations on at least one occasion of > 440 msec, a 
reasonable threshold for caution (24, 26, 27, 33, 34), and three of > 450 msec, a value 
concerning enough to have excluded candidates from our study if present at screening. 
One child experienced prolongation of 114 msec while on ziprasidone, which is well over 
both the 75 msec increase suggested by Morganroth (27) as clinically significant in 
adults, and the 60-msec increase set by the The Committee for Proprietary Medicinal 
Products (37) as significant for risk of arrhythmia. Based upon that prolongation, and 
upon the fact that three of 20 subjects experienced episodes of prolongation > 450 msec, 
we can reject the null hypothesis regarding ziprasidone and conclude that in low doses it 
does cause clinically significant prolongation in the QTc in pediatric patients. Finally, all 
of these findings occurred at low dosage. Though we did not demonstrate statistically 
significant dose dependence, other studies have found this phenomenon in adults (77). If 
this phenomenon does hold in children, and if peak increases at doses of 40-60 mg/day 
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were 28 msec, they might be much greater at today’s doses, which often range from 80- 
160 mg/day (Andres Martin, personal communication). 
A note on calculations should be made. Depending upon how other studies 
derived their numbers representing prolongation, our result may be more conservative 
and risks a type I error. For each patient, we obtained a value of maximum prolongation 
by subtracting the unmedicated value of QTc from the single highest value of QTc 
attained while on drug. We then summed these numbers and divided by our n of 20 to 
obtain 28 msec. It is possible that other studies obtained their mean number by 
comparing each patient’s baseline to not just his highest value, but to all higher values of 
QTc; or even all other values of QTc, including those that dropped below baseline; and 
dividing by total number of ECGs rather than total number of patients. Sources 
describing the manufacturer’s study of ziprasidone do not make this distinction clear (76, 
77). Neither does the study that found an 11 msec increase (78). Because our priority 
was to avoid a type II error - that of failing to reject the null hypothesis due to missing 
prolongation - we felt it prudent to look at peak values of QTc rather than averaging all 
increases together, since if it only takes one episode of prolongation to put a patient at 
risk, then a drug’s maximum capacity to prolong the QTc is more important than what it 
does on average. This methodology may, however, run the risk of incurring a type I error 
- that of finding an effect erroneously and falsely rejecting the null hypothesis. 
On a mechanistic note, in light of ziprasidone’s probable mechanism of 
prolongation - that of blockade of the fast component of the delayed rectifier potassium 
channel (5) - it is interesting to consider that statistically significant prolongation of the 
QRS interval was not found in our subjects. The channel, encoded by the HERG gene, is 
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important during repolarization, but not depolarization - the latter being represented on 
the ECG by the QRS complex. Our findings lend strength to the idea that HERG 
blockade during repolarization is predominantly responsible for QTc prolongation by 
ziprasidone. 
Though there were too few females in our study for a subgroup analysis, it is 
interesting to note that the subject with the longest baseline and medicated QTc intervals 
- often in the 440s - was a nineteen-year-old female. The QTc is known to be longer in 
postpubertal women than in men (10, 14, 25); possibly this effect applies to adolescent 
girls. Another possible explanation for prolongation in our subject could be related to 
dose, since her doses ranged up to 60 mg/day, unlike the other subjects whose maximum 
was 40 mg/day. Again, however, we did not detect a significant dose-response effect in 
this small study. 
Because of the mean degree of peak prolongation, the fact that 3 of 20 children 
had prolongations over 450 msec and one had a 114-msec prolongation, and the fact that 
these changes occurred at low doses when a dose-dependent effect on prolongation has 
been noted in adults (77), clinicians must carefully weigh the decision to use ziprasidone. 
They may want to consider reserving it as a second- or third-line drug, particularly in 
patients with underlying risk factors for QTc prolongation, and particularly in light of the 
high doses that are standard in current practice and the risk of overdose. They will have 
to balance this possible increased risk of arrhythmia and sudden death with the evidence 
that ziprasidone may have fewer adverse effects, such as weight gain (75), than other 
drugs of its kind. Should they decide to use ziprasidone, clinicians should take 
precautions to avoid missing drug-induced QTc prolongation or a baseline congenital 
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prolongation. They are strongly advised to screen and monitor patients taking 
ziprasidone with ECGs according to clinical guidelines, including careful history-taking, 
sensible ECG practices, and consultation with a pediatric cardiologist for interpretation 
and for manual measurement of the QTc interval. 
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FIGURE 1 
QTc interval measurement by two methods (milliseconds) 
Number of electrocardiograms = 134 
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TABLE 1 
Overview of electrocardiographic monitoring in pediatric psychopharmacology 
1. If considering one of these drugs, schedule a screening visit, 
a. For TCAs: Reserve as second- or third-line therapy. 
2. Screening visit: Complete history and physical (13, 167, 202). 
a. History 
i. Symptoms: syncope (202), near-syncope, palpitations (187)? If 
yes, consider referral to pediatric cardiologist for workup of possible congenital 
LQTS (167). 
ii. Heart problems? If yes, do not prescribe clonidine (202); consider 
consult with pediatric cardiologist if considering other meds. 
iii. Renal disease? If yes, do not prescribe clonidine (202). 
iv. Is the child taking any other medications? Consider potentially 
dangerous interactions (see Table 3 for examples) (167, 187). 
v. For antipsychotics especially: Inquire about cardiac risk factors. 
b. Family history: Consider consult with pediatric cardiologist if positive for: 
i. Heart disease, sudden/unexplained death, LQTS, deafness, 
tachydysrhythmias, seizures, syncope (167, 187, 202). 
ii. For TCAs especially: AV block, IV conduction delay, Wolff- 
Parkinson-White syndome or other conduction problems, structural problems, 
rhythm disturbances. 
c. Physical exam 
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i. Measure vital signs. If pulse < 60 or BP > 2 standard deviations 
above age norms, consider consult with pediatric cardiologist (167, 203, 204). 
ii. Heart murmurs? If not innocent, refer to pediatric cardiologist 
(202). 
iii. For antipsychotics especially: Measure weight. 
iv. ECG general guidelines: Obtain before breakfast to avoid 
midaftemoon T-wave changes (38, 147). In adults at least the QTc is longer after 
a meal (205); avoid postprandial ECGs. Attempt to obtain at physiologic heart 
rates to avoid inaccuracy in Bazett correction. For TCAs, phenothiazine 
antipsychotics, and pimozide especially: obtain baseline ECG (167). Parameters 
should include PR less than or equal to 200 msec and QRS duration less than or 
equal to 120 msec (187). Choose alternate therapy, if possible, if QTc >450 msec. 
Avoid pimozide if QTc >440 msec (144, 206). Consider obtaining ECG before 
prescribing clonidine; not all authorities agree (167, 207). Kowatch and DelBello 
(106) recommend a baseline ECG before starting ziprasidone, as does this author. 
d. Laboratory data 
i. For clonidine: CBC/diff, lytes/BUN/Cr/fasting glucose, TFTs, 
LFTs (203), also K, Mg (4). 
ii. For antipsychotics: Electrolytes/BUN/Cr/fasting glucose, LFTs, 
lipids, Ca, Mg (147). 
e. Educate family about proposed drug’s risks and benefits, as well as signs 
and symptoms of possible adverse reactions, and about the need to avoid P450 
interactions with other drugs. 
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3. If all is well, begin drug at lowest possible therapeutic dose (13). Consider drug 
interactions: for example, with alpha agonists,avoid beta-blockers (165). Also, stop them 
before stopping clonidine (202), and use TCAs and CNS depressants with caution. 
4. Follow-up visits: 
a. History 
i. Symptoms: Syncope, near-syncope, palpitations? For alpha- 
agonists especially: dizziness, fatigue, lightheadedness, sedation. If yes, 
especially with exercise, consider referral to pediatric cardiologist for Holter 
monitoring and echocardiography (204). Also for alpha agonists: Ask about 
withdrawal symptoms, such as tachycardia and tachypnea. Ask about fatigue, 
bradycardia, diminished blood pressure. If present, decrease dose. 
ii. Other medications? If so, consider possible interactions (167). 
For TCAs, obtain blood levels. 
b. Physical 
i. Measure vital signs, including orthostatic set. Refer to pediatric 
cardiologist and consider alternate therapy if HR>130. For alpha agonists, if 
orthostatic change in pulse or increase in BP of greater than 10%, exercise caution 
with dose increases (202). 
ii. For antipsychotics, in case of dose change, addition of new drug, 
or attainment of steady-state (167, 187), get plasma levels and ECG. QTc should 
be less than 450 msec. Refer to pediatric cardiologist and consider alternate 
therapy if resting heart rate > 130, PR>200, QRS>120 (or >25% change from 
baseline value), QTc > 450 (167) or an increase in QTc from baseline of > 60 
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msec (37). Other ECG abnormalities should prompt lowering of dose and serial 
monitoring (167). If T-wave inversions, arrhythmias, or U-waves present, 
discontinue pimozide, then obtain repeat ECG (144, 206). 
iii. Consider monitoring K and Mg, especially during diarrheal illness 
and with ziprasidone; correct as needed (76). 
iv. Francis (187) recommends ascertaining hepatic and renal function 
after changes in dosage. 
v. For antipsychotics: Fayek et al (147) recommend repeating 
baseline labs mentioned above on at least a yearly basis. 
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TABLE 2 
Summary guidelines for electrocardiographic monitoring in pediatric 
psychopharmacology 
1. Baseline ECG to rule out underlying abnormalities. 
2. At a minimum, repeat the ECG at 
a. Projected target dose (e.g., 5 mg/kg/day of imipramine) 
b. Halfway to projected target dose 
c. After any clinical suspicion (e.g., patient reports “skipped beats”) 
d. At steady state, every three months during the first six months of steady- 
state, and every six months thereafter. 
e. For clonidine, if bradycardia, impaired AV conduction, or QRS > 120 
msec, consider referral to pediatric cardiologist. 
3. Monitor ECG in case of overdose. 
4. Pay particular attention to: 
a. Heart rate >130 bpm 
b. PR > 200 msec 
c. QRS > 120 msec (or >25% change from baseline value), 
d. QTc > 450 msec, 
e. QTc increase from baseline of > 60 msec. 
5. Bear in mind that manual measurements of intervals are more accurate than 
intervals measured by the ECG machine. 
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TABLE 3 
Examples of potentially dangerous pharmacotherapeutic combinations 
Drug Potential adverse effect 
Tricyclics (TCAs)a (208) 
plus serotonin-selective reuptake inhibitor TCA toxicity due to increased levels 
plus monoamine oxidase inhibitor 
Hypertensive crisis, convulsions, 
hyperpyrexia, coma 
plus neuroleptics TCA toxicity due to increased levels 
plus low-potency neuroleptics Anticholinergic effects 
Alpha agonists (202) 
plus beta blocker 
Rebound hypertension if beta blocker 
withdrawn 
plus TCA 
Changes in sinus node conduction 
(controversial) 
plus CNS depressants or sedatives Potentiation of sedative-hypnotic effect 
Antipsychotics15 (121) 
Olanzapine, clozapine, or pimozide plus 
CYP1A2 inhibitor, such as fluvoxamine 
Increase in antipsychotic drug levels 
Clozapine, haloperidol, pimozide, or 
ziprasidone plus CYP3A4 inhibitor, such 
as clarithromycin 
Increase in antipsychotic drug levels 
c Combinations of medications that both prolong the QTc interval should be avoided. 
AFor a more detailed and complete list of interactions of TCAs with other medications, 
see Gundersen and Geller (208). 
For a detailed website on drugs involved in cytochrome P450 interactions, see page at 
University of Indiana/Purdue University at Indianapolis (209). 
c For a detailed website on QTc-prolonging medications, see page at Arizona CERT 
(210). 

TABLE 4 
Sample dosing schedule 
Day AM dose (mg) PM dose (mg) 
1 0 5 
4 5 5 
8 5 10 
14 10 10 
18 10 15 
21 15 15 
28 20 20 
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TABLE 5 
Number of ECGs with prolonged QTc intervals (> 440 ms) 
as determined by two methods 
Manual measurement 
Not prolonged Prolonged Total 
Automated 
measurement 
Not prolonged 117 9 126 
Prolonged 5 3 8 
Total 122 12 134 
Note: Percent agreement = 3/(5+9+3) = 3/17 = 18%; kappa = 25. 
Sensitivity = 3/(3+9) = 25%. 
Specificity = 117/(5+117) = 95%. 
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TABLE 6 
ECG changes between baseline and peak values 
ECG 
para¬ 
meter 
Baseline Peak values Change % Change Statistic 
Mean 
(SD) Range 
Mean 
(SD) Range 
Mean 
(SD) Max 
Mean 
(SD) Max t P 
HR 
(bpm) 78(18) (50,117) 92(19) (65,149) 14(11) 38 20(18) 76 5.64 <.001 
PR 
(ms) 133(21) (100,177) 148(16) (122,187) 14(14) 50 12(13) 47 4.62 <.001 
QRS 
(ms) 82(9) (54,103) 82(8) (54,91) 0(7) 10 1(7) 12 0.17 0.87 
QTc 
(ms) 402(29) (328,449) 430(21) (397,470) 28(26) 114 7(8) 35 4.71 <0.01 
Note: ECG, electrocardiogram; SD, standard deviation; HR, heart rate; bpm, beats per 
minute; ms, milliseconds; Max, maximum; QTc, corrected QT (Bazett method). 
Number of subjects = 20. 
Number of manually-measured electrocardiograms = 176. 
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QTc values over time of subjects with values > 440 msec 
(manual measurement) 
Time 
Subject identification number, age (yr), sex 
#35 
13, M 
#37 
13, M 
#38 
9, M 
#41 
13, F 
#43 
16, M 
#47 
19, F 
#48 
17, M 
#49 
16, M 
Screening 328 432 384 436 391 421/445a 430 436 
Day 7 362 422 419 421 450 437 401 438 
Day 14 334 470 408 414 399 429 394 444 
Day 21 358 366 414 393 420 446 423 
Day 28 350 367 443 425 449 436 405 
Day 42 432 
Day 56 388 448 427 435 420 416 
Month 3 379 428 451 440 339 423 
Month 4 442 362 453 440 406 
Month 5 373 402 440 417 400 415 
Month 6 387 414 400 439 446 440 
APatient received two pre-medication EKGs. 
Note: M, male; F, female. 
Some patients received fewer EKGs owing to trial discontinuation. 
Values > 450 msec are bolded. 
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TABLE 8 
Patients experiencing discrete increases over baseline: 
Manufacturer vs. current study 
QTc increase 
over baseline 
(msec) 
Number of subjects (%) 
P Manufacturer 
(77) 
(n = 33) 
Current study 
(n = 20) ' 
>30 21(64) 8 (40) 0.082 
>60 7(21) 1 (5) 0.112 
>75 1 (3) 1 (5) 0.617 
Note: Patients with greater changes were also counted in groups of lesser change. 
When patients received two pre-medication EKGs in our study, the lower baseline 
QTc was used to calculate changes. 
p refers to results of chi-square test (in 30-msec group) or Fisher’s exact test (in 
60 and 75-msec groups). 
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